Results 191 to 200 of about 10,935,890 (352)
RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies
Molecular Oncology, EarlyView.RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho +10 morewiley +1 more sourceNicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling
Molecular Oncology, EarlyView.AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu +5 morewiley +1 more sourceGlobal, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study
JAMA Oncology, 2017 C. Fitzmaurice, Christine Allen, Ryan Barber, L. Barregard, Z. Bhutta, H. Brenner, D. Dicker, Odgerel Chimed-Orchir, R. Dandona, L. Dandona, T. Fleming, M. Forouzanfar, Jamie Hancock, Roderick J Hay, Rachel Hunter-Merrill, Chantal K Huynh, H. Hosgood, C. Johnson, J. Jonas, J. Khubchandani, G. Kumar, Michael Kutz, Q. Lan, H. Larson, Xiaofeng Liang, Stephen S. Lim, Alan D. Lopez, Michael F. MacIntyre, L. Marczak, N. Marquez, A. Mokdad, Christine Pinho, F. Pourmalek, J. Salomon, J. Sanabria, Logan Sandar, B. Sartorius, S. Schwartz, K. Shackelford, K. Shibuya, J. Stanaway, C. Steiner, Jiandong Sun, Ken Takahashi, S. Vollset, T. Vos, Joseph A Wagner, Haidong Wang, R. Westerman, H. Zeeb, Leo Zoeckler, F. Abd-Allah, M. Ahmed, S. Alabed, N. Alam, S. Aldhahri, Girma Alem, Mulubirhan Assefa Alemayohu, R. Ali, Rajaa Al-Raddadi, Azmeraw T. Amare, Y. Amoako, A. Artaman, H. Asayesh, N. Atnafu, A. Awasthi, H. Saleem, A. Barać, Neeraj Bedi, I. Benseñor, A. Berhane, E. Bernabé, B. Betsu, A. Binagwaho, D. Boneya, Ismael Campos-Nonato, C. Castañeda-Orjuela, F. Catalá-López, P. Chiang, C. Chibueze, Abdulaal Chitheer, J. Choi, B. Cowie, S. Damtew, J. D. das Neves, S. Dey, S. Dharmaratne, P. Dhillon, E. Ding, T. Driscoll, D. Ekwueme, A. Endries, M. Farvid, F. Farzadfar, João Fernandes, F. Fischer, Tsegaye Tewelde G/hiwot, A. Gebru, S. Gopalani, A. Hailu, M. Horino, N. Horita, A. Husseini, I. Huybrechts, M. Inoue, F. Islami, M. Jakovljevic, S. James, Mehdi Javanbakht, S. Jee, A. Kasaeian, Muktar Sano Kedir, Y. Khader, Y. Khang, Daniel H. Kim, J. Leigh, S. Linn, R. Lunevicius, Hassan Magdy Abd El Razek, R. Malekzadeh, D. Malta, W. Marcenes, D. Markos, Y. Melaku, K. G. Meles, W. Mendoza, Desalegn Tadese Mengiste, T. Meretoja, T. Miller, K. Mohammad, A. Mohammadi, S. Mohammed, M. Moradi-Lakeh, G. Nagel, D. Nand, Q. L. Le Nguyen, Sandra Nolte, F. Ogbo, K. Oladimeji, Eyal Oren, Mahesh Pa, Eun‐Kee Park, David M Pereira, D. Plass, M. Qorbani, A. Radfar, Anwar Rafay, Mahfuzar Rahman, S. Rana, K. Søreide, Maheswar Satpathy, M. Sawhney, S. Sepanlou, M. Shaikh, Jun She, I. Shiue, H. Shore, M. Shrime, S. So, S. Soneji, V. Stathopoulou, K. Stroumpoulis, M. Sufiyan, Bryan L. Sykes, R. Tabarés-Seisdedos, Fentaw Tadese, B. Tedla, G. Tessema, J. S. Thakur, B. Tran, K. Ukwaja, B. Uzochukwu, V. Vlassov, E. Weiderpass, Mamo Wubshet Terefe, Henock G. Yebyo, H. H. Yimam, N. Yonemoto, M. Younis, Chuanhua Yu, Z. Zaidi, M. Zaki, Z. M. Zenebe, C. Murray, M. Naghavi +184 moresemanticscholar +1 more sourcePARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer +21 morewiley +1 more source
